# Staccato Alprazolam Abuse Liability

> **NCT00603980** · PHASE1 · COMPLETED · sponsor: **Nova Pneuma Inc.** · enrollment: 31 (actual)

## Conditions studied

- Abuse Liability of Staccato Alprazolam

## Interventions

- **DRUG:** Inhaled placebo + oral placebo
- **DRUG:** Inhaled alprazolam 0.5 mg
- **DRUG:** Inhaled alprazolam 1 mg
- **DRUG:** Inhaled alprazolam 2 mg
- **DRUG:** Oral alprazolam 1 mg
- **DRUG:** Oral alprazolam 2 mg
- **DRUG:** Oral alprazolam 4 m
- **DRUG:** Oral alprazolam 2 mg qualifying session
- **DRUG:** Oral placebo qualifying session

## Key facts

- **NCT ID:** NCT00603980
- **Lead sponsor:** Nova Pneuma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603980, "Staccato Alprazolam Abuse Liability". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00603980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*